Efficacy of codelivery of dual AAV2/5 vectors in the murine retina and hippocampus

Human Gene Therapy

Volumn 23, Issue 8, 2012, Pages 847-858

  Palfi, Arpad ^a,b   Chadderton, Naomi ^a   McKee, Alex G ^a   Blanco Fernandez, Alfonso ^b   Humphries, Peter ^a   Kenna, Paul F ^a   Farrar, G Jane ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; MESSENGER RNA; RED FLUORESCENT PROTEIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; HIPPOCAMPUS; HUMAN; HUMAN CELL; MALE; MICROSCOPY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; RETINA CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DEPENDOVIRUS; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; HELA CELLS; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR; RETINA; TRANSDUCTION, GENETIC;

EID: 84865219047     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.142     Document Type: Article

References (62)

1. Allocca, M., Doria, M., Petrillo, M., et al. (2008). Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J. Clin. Invest. 118, 1955-1964.
2. Auricchio, A., Kobinger, G., Anand, V., et al. (2001). Exchange of surface proteins imparts on viral cellular specificity and transduction characteristics: The retina as a model. Hum. Mol. Genet. 10, 3075-3081.
3. Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amau-rosis. N. Engl. J. Med. 22;358, 2231-2239.
4. Bennicelli, J., Wright, J.F., Komaromy, A., et al. (2008). Reversal of blindness in animal models of Leber congenital amaurosis using optimized AAV2-mediatedgenetransfer. Mol. Ther.16, 458-465.
5. Buch, P.K., MacLaren, R.E., Durán, Y., et al. (2006). In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. Mol. Ther. 14, 700-709.
6. Burger, C., Gorbatyuk, O.S., Velardo, M.J., et al. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10, 302-317.
7. Busskamp, V., Duebel, J., Balya, D., et al. (2010). Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 329, 413-417.
8. Caporale, N., Kolstad, K.D., Lee, T., et al. (2011). LiGluR restores visual responses in rodent models of inherited blindness. Mol. Ther. 19, 1212-1219.
9. Cepko, C. (2010). Neuroscience: Seeing the light of day. Science 329, 403-404.
10. Chadderton, N., Millington-Ward, S., Palfi, A., et al. (2009). Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol. Ther. 17, 593-599.
11. Christine, C.W., Starr, P.A., Larson, P.S., et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662-1669.
12. Dong, B., Nakai, H., and Xiao, W. (2010). Characterization of genome integrity for oversized recombinant AAV vector. Mol. Ther. 18, 87-92.
13. Dong, J.Y., Fan, P.D., and Frizzell, R.A. (1996). Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7, 2101-2112.
14. Doonan, F., Donovan, M., and Cotter, T.G. (2005). Activation of multiple pathways during photoreceptor apoptosis in the rd mouse. Invest. Ophthalmol. Vis. Sci. 46, 3530-3538.
15. Duan, D., Yue, Y., Yan, Z., and Engelhardt, J.F. (2000). A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermo-lecular cis activation. Nat. Med. 6, 595-598.
16. Fan, D.S., Ogawa, M., Fujimoto, K.I., et al. (1998). Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic l-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. 9, 2527-2535.
17. Farrar, G.J., Palfi, A., and O'Reilly, M. (2010). Gene therapeutic approaches for dominant retinopathies. Curr. Gene Ther. 10, 381-388.
18. Gao, G., Vandenberghe, L.H., and Wilson, J.M. (2005). New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285-297.
19. Ghosh, A., Yue, Y., and Duan, D. (2006). Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J. Gene Med. 8, 298-305.
20. Ghosh, A., Yue, Y., Shin, J.H., and Duan, D. (2009). Systemic trans-splicing adeno-associated viral delivery efficiently transduces the heart of adult mdx mouse, a model for Du-chenne muscular dystrophy. Hum. Gene Ther. 20, 1319-1328.
21. Halbert, C.L., Allen, J.M., and Miller, A.D. (2002). Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat. Biotechnol. 20, 697-701.
22. Hamel, C.P. (2007). Cone rod dystrophies. Orphanet J. Rare Dis. 2, 7.
23. Hartong, D.T., Berson, E.L., and Dryja, T.P. (2006). Retinitis pigmentosa. Lancet 368, 1795-1809.
24. Hauswirth, W.W., Aleman, T.S., Kaushal, S., et al. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum. Gene Ther. 19, 979-990.
25. Jacobson, S.G., Acland, G.M., Aguirre, G.D., et al. (2006). Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol. Ther. 13, 1074-1084.
26. Jeon, C.J., Strettoi, E., and Masland, R.H. (1998). The major cell populations of the mouse retina. J. Neurosci. 18, 8936-8946.
27. Kay, M.A. (2011). State-of-the-art gene-based therapies: The road ahead. Nat. Rev. Genet. 12, 316-328.
28. Kim, D.H., and Rossi, J.J. (2003). Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev. 13, 151-155.
29. Komeima, K., Rogers, B.S., and Campochiaro, P.A. (2007). An-tioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J. Cell Physiol. 213, 809-815.
30. Kubodera, T., Yamada, H., Anzai, M., et al. (2011). In vivo application of an RNAi strategy for the selective suppression of a mutant allele. Hum. Gene Ther. 22, 27-34.
31. Lagali, P.S., Balya, D., Awatramani, G.B., et al. (2008). Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat. Neurosci. 11, 667-675.
32. Lai, Y., Yue, Y., and Duan, D. (2010). Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome ‡ 8.2 kb. Mol. Ther. 18, 75-79.
33. Li, W., Asokan, A., Wu, Z., et al. (2008). Engineering and selection of shuffled AAV genomes: A new strategy for producing targeted biological nanoparticles. Mol. Ther. 16, 1252-1260.
34. Li, X.G., Okada, T., Kodera, M., et al. (2006). Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol. Ther. 13, 160-166.
35. Li, Y., Tao, W., Luo, L., et al. (2010). CNTF induces regeneration of cone outer segments in a rat model of retinal degeneration. PLoS One 5, e9495.
36. MacLachlan, T.K., Lukason, M., Collins, M., et al. (2011). Pre-clinical safety evaluation of AAV2-sFLT01: A gene therapy for age-related macular degeneration. Mol. Ther. 19, 326-334.
37. Maguire, A.M., Simonelli, F., Pierce, E.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248.
38. Maheshri, N., Koerber, J.T., Kaspar, B.K., and Schaffer, D.V. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204.
39. Mandel, R.J. (2010). CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr. Opin. Mol. Ther. 12, 240-247.
40. Mao, H., Gorbatyuk, M.S., Rossmiller, B., et al. (2012). Long term rescue of retinal structure and function in P23H RHO trans-genic mice by rhodopsin RNA replacement with a single AAV vector. Hum. Gene Ther. 23, 356-366.
41. Marks, W.J., Jr., Ostrem, J.L., Verhagen, L., et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol. 7, 400-408.
42. McCarty, D.M. (2008). Self-complementary AAV vectors: Advances and applications. Mol. Ther. 16, 1648-1656.
43. McKee, A.G., Loscher, J.S., O'Sullivan, N.C., et al. (2010). AAV-mediated chronic over-expression of SNAP-25 in adult rat dorsal hippocampus impairs memory-associated synaptic plasticity. J. Neurochem. 112, 991-1004
44. Millington-Ward, S., O'Neill, B., Tuohy, G., et al. (1997). Stratagems in vitro for gene therapies directed to dominant mutations. Hum. Mol. Genet. 6, 1415-1426.
45. Millington-Ward, S., Chadderton, N., O'Reilly, M., et al. (2011). Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol. Ther. 19, 642-649.
46. Monahan, P.E., Lothrop, C.D., Sun, J., et al. (2010). Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: A strategy for broad clinical application. Mol. Ther.18, 1907-1916.
47. Muramatsu, S., Fujimoto, K., Ikeguchi, K., et al. (2002). Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 13, 345-354.
48. Musarella, M.A. (2001). Molecular genetics of macular degeneration. Doc. Ophthalmol. 102, 165-177.
49. O'Reilly, M., Palfi, A., Chadderton, N., et al. (2007). RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am. J. Hum. Genet. 81, 127-135.
50. Palfi, A., Ader, M., Kiang, A.S., et al. (2006). RNAi-based suppression and replacement of rds-peripherin in retinal orga-notypic culture. Hum. Mutat. 27, 260-268.
51. Palfi, A., Millington-Ward, S., Chadderton, N., et al. (2010). AAV-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. Hum. Gene Ther. 21, 311-323.
52. Pawlyk, B.S., Smith, A.J., Buch, P.K., et al. (2005). Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest. Ophthalmol. Vis. Sci. 46, 3039-3045.
53. Provost, N., Le Meur, G., Weber, M., et al. (2005). Biodistribution of rAAV vectors following intraocular administration: Evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol. Ther. 11, 275-283.
54. Reich, S.J., Auricchio, A., Hildinger, M., et al. (2003). Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum. Gene Ther. 14, 37-44.
55. Stieger, K., Colle, M.A., Dubreil, L., et al. (2008). Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol. Ther. 16, 916-923.
56. Stieger, K., Schroeder, J., Provost, N., et al. (2009). Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol. Ther. 17, 516-523.
57. Wu, Z., Yang, H., and Colosi, P. (2010). Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80-86.
58. Yan, D., and Liu, X.Z. (2010). Genetics and pathological mechanisms of Usher syndrome. J. Hum. Genet. 55, 327-335.
59. Yan, Z., Zhang, Y., Duan, D., and Engelhardt, J.F. (2000). Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 97, 6716-6721.
60. Yang, G.S., Schmidt, M., Yan, Z., et al. (2002). Virus-mediated transduction of murine retina with adeno-associated virus: Effects of viral capsid and genome size. J. Virol. 76, 7651-7660.
61. Yang, Y., Mohand-Said, S., Danan, A., et al. (2009). Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol. Ther. 17, 787-795.
62. Zhong, L., Li, B., Mah, C.S., et al. (2008). Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A. 105, 7827-7832.